Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Julphar
Baxter
Dow
Colorcon
Citi
Johnson and Johnson
US Army
Accenture

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,236,804

« Back to Dashboard

Which drugs does patent 8,236,804 protect, and when does it expire?

Patent 8,236,804 protects VIIBRYD and is included in one NDA.

This patent has fifty-eight patent family members in twenty-nine countries.
Summary for Patent: 8,236,804
Title:Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Abstract: The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine- , crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.
Inventor(s): Bathe; Andreas (Darmstadt, DE), Helfert; Bernd (Ober-Ramstadt, DE), Neuenfeld; Steffen (Messel, DE), Kniel; Heike (Heppenheim, DE), Bartels; Matthias (Darmstadt, DE), Rudolph; Susanne (Dieburg, DE), Bottcher; Henning (Darmstadt, DE)
Assignee: Merck Patentgesellschaft (Darmstadt, DE)
Application Number:13/100,948
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,236,804
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,236,804

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-001 Jan 21, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-002 Jan 21, 2011 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,236,804

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01113647Jun 19, 2001

Non-Orange Book US Patents Family Members for Patent 8,236,804

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,921,375 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride ➤ Sign Up
7,981,894 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride ➤ Sign Up
7,381,726 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride ➤ Sign Up
8,673,921 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
US Department of Justice
Cipla
Citi
Fish and Richardson
Federal Trade Commission
Teva
Mallinckrodt
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.